Y-mAbs Therapeutics, Inc.
YMABDelisted Sep 16, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001722964
Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Y-mAbs Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +8 vs. Q3 2024
- Shares held
- 28.8M
- +3.06M (+11.9%) vs. Q3 2024
- Total value
- $225.5M
- −$113.1M (−33.4%) vs. Q3 2024
- New holders
- 19
- 39 more added
- Sold out
- 11
- 31 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting YMAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 2 | $78.3K |
| Q2 2025 | 97 | $125.9M |
| Q1 2025 | 103 | $127.6M |
| Q4 2024 | 113 | $225.5M |
| Q3 2024 | 105 | $338.5M |
| Q2 2024 | 96 | $294.2M |
| Q1 2024 | 96 | $374.0M |
| Q4 2023 | 94 | $138.0M |
| Q3 2023 | 99 | $107.3M |
| Q2 2023 | 95 | $132.4M |
| Q1 2023 | 86 | $95.4M |
| Q4 2022 | 91 | $94.2M |
| Q3 2022 | 100 | $339.7M |
| Q2 2022 | 91 | $374.7M |
| Q1 2022 | 88 | $300.6M |
| Q4 2021 | 97 | $417.1M |
| Q3 2021 | 97 | $749.0M |
| Q2 2021 | 100 | $886.9M |
| Q1 2021 | 117 | $804.8M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Y-mAbs Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| D. E. Shaw & Co., Inc. | 615,131 | $4.82M | 0.01% | −172,405−21.9% | Reduced |
| Boothbay Fund Management, LLC | 693,693 | $5.43M | 0.17% | +136,264+24.4% | Added |
| Pictet Asset Management Holding SA | 756,297 | $5.92M | 0.01% | +68,317+9.9% | Added |
| Geode Capital Management, LLC | 822,309 | $6.44M | 0.00% | +8,820+1.1% | Added |
| Logos Global Management LP | 1,000,000 | $7.83M | 0.92% | +200,000+25.0% | Added |
| State Street Corp | 1,314,409 | $10.3M | 0.00% | +104,628+8.6% | Added |
| Caligan Partners LP | 1,767,982 | $13.8M | 3.51% | +572,729+47.9% | Added |
| Polar Capital Holdings Plc | 1,831,000 | $14.3M | 0.08% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,000,022 | $15.7M | 0.00% | −35,341−1.7% | Reduced |
| Sofinnova Investments, Inc. | 2,194,278 | $17.2M | 1.26% | 00.0% | Unchanged |
| Acorn Capital Advisors, LLC | 2,861,825 | $22.4M | 12.06% | +2,861,825 | New |
| BlackRock, Inc. | 2,998,472 | $23.5M | 0.00% | −26,763−0.9% | Reduced |
| Paradigm Biocapital Advisors LP | 4,236,346 | $33.2M | 1.15% | +150,000+3.7% | Added |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −105,777−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −94,225−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −17,071−100.0% | Sold out |
| Empire Financial Management Company, LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −14,260−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −4,218−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −31−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −3−100.0% | Sold out |